Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810105 · ClinicalTrials.gov registry record · Phase 2
A Study of Olaparib and Durvalumab in Prostate Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03810105: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03810105 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03810105, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
Interventions
- DRUG Olaparib
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03810105
The ClinicalTrials.gov registry entry for NCT03810105 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT03810105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03810105 about?
NCT03810105 is a clinical study titled "A Study of Olaparib and Durvalumab in Prostate Cancer". The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
What is the current status of trial NCT03810105?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-03-07. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT03810105?
The interventions under investigation include: Olaparib (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03810105?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.